Earnings Releases·Oct 28, 2026, 4:05 PM ET

ClearPoint Neuro — Third Quarter 2026 Earnings Summary

Total revenue reached $12.1 million, a 36% year-over-year increase driven by a 59% rise in neurosurgery navigation and therapy revenue and a 68% surge in capital equipment and software, while gross margin declined to 58% from 63% due to new facility overhead and intangible asset amortization.
The company reported a net loss of $7.46 million ($0.24 per share) compared to $5.89 million ($0.21 per share) in the prior year period, with operating expenses rising 23% to $13.4 million primarily due to the IRRAS acquisition and higher personnel costs.
Full-year 2026 revenue guidance is maintained between $48.0 million and $50.0 million, supported by a cash balance of $46.2 million and a strategic focus on expanding its comprehensive drug delivery ecosystem.
Strategic milestones include the submission of a Biologics License Application (BLA) for Huntington's Disease treatment, the acquisition of the IRRAflow portfolio in Q4 2025, and a $2.98 million NCI R01 grant award for MR-guided laser therapy research.